Pharma has long marketed opioids in ways that contribute to opioid use disorder and deaths by overdose. Regulatory mistakes in approving and labeling new analgesics by the FDA didn’t make us safer.
AMA J Ethics. 2020;22(8):E743-750. doi:
10.1001/amajethics.2020.743.
Dr Travis Rieder discusses his own experiences with opioids and the ethical challenges of “legacy patients,” and Dr Stephanie Zaza, president of the American College of Preventive Medicine, discusses the future of opioid research priorities.
A nudge is an intervention designed to prompt a person to “voluntarily” make a choice intended by those who altered an environment or situation to yield that choice.
AMA J Ethics. 2020;22(9):E767-772. doi:
10.1001/amajethics.2020.767.
Dr Joshua D. Safer joins Ethics Talk to discuss his article, coauthored with Rebkah Tesfamariam: “How Should a Transgender Patient’s History of Deep Vein Thrombosis and Smoking Influence Gender-Affirming Health Decision Sharing?”
Palliative psychiatry can facilitate compassionate resolution of ethical conflicts in end-of-life care decision making with persons with substance use disorders.
AMA J Ethics. 2023;25(9):E678-683. doi:
10.1001/amajethics.2023.678.
This commentary on a case considers a transgender patient’s mental health and risk for DVT in ethical decision making about feminizing gender-affirming hormone therapy.
AMA J Ethics. 2023;25(6):E386-390. doi:
10.1001/amajethics.2023.386.